Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of JX11502MA in Healthy Volunteers
NCT05233657Phase 1Unknown
- Sponsor
- Jingxin Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing JX11502MA with Placebo (2 arms). Primary endpoint: Incidence rate of adverse reactions. Status: unknown.
02
Drugs
JX11502MA
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05233657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233657.